Search - tctmd.com

Displaying 41 - 60 of 109

Sort: Relevancy | Date

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

December 27, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

August 04, 2021

Apixaban May Be Best DOAC for Frail, Older Patients With AF

News Daily News

Apixaban May Be Best DOAC for Frail, Older Patients With AF

July 19, 2021

DOACs May Have Advantage Over VKAs After TAVI, Study Hints

News Daily News

DOACs May Have Advantage Over VKAs After TAVI, Study Hints

July 14, 2021

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

June 22, 2021

TCTMD’s Top 10 Most Popular Stories for May 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2021

May 31, 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

Observational Study Supports Continuing Oral Anticoagulation During PCI

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

News Daily News

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

March 17, 2021

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

News Conference News TCT 2020

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

Michael O'Riordan

October 14, 2020

ABC-Bleeding Score Stratifies Risk in A-fib Patients on OAC and Aspirin

News Daily News

ABC-Bleeding Score Stratifies Risk in A-fib Patients on OAC and Aspirin

September 21, 2020

Systemic Anticoagulation Linked to Lower Mortality in Hospitalized COVID-19

News Daily News

Systemic Anticoagulation Linked to Lower Mortality in Hospitalized COVID-19

Michael O'Riordan

August 28, 2020

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

June 25, 2020

More Evidence of Lower Fracture Risk With DOACs Versus Warfarin

News Daily News

More Evidence of Lower Fracture Risk With DOACs Versus Warfarin

May 19, 2020

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.